MODEL VERDICT
Rocket Pharmaceuticals, Inc. (RCKT)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| Jan 11, 2026 | MODERATE | 0.65 | $3.73 | CURRENT | -6.4% |
| Dec 12, 2025 | MODERATE | 0.66 | $3.39 | Scaled in | +45.1% |
| Nov 12, 2025 | MODERATE | 0.66 | $3.30 | Monitoring | -3.0% |
| Oct 13, 2025 | MODERATE | 0.66 | $3.47 | Scaled in | +7.5% |
| Sep 13, 2025 | MODERATE | 0.65 | $3.16 | Scaled in | +7.3% |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| P/TBV | 3.94 | 3.26 | 1.83 | 6.42 | 1.65 |
| P/B Ratio | 3.50 | 3.04 | 1.41 | 6.03 | 1.59 |
Insufficient data to determine relative valuation for RCKT.
Fair value could not be computed for RCKT due to insufficient comparable data.
RCKT's current P/E of -1.8x compares to the industry median of 25.9x (2 peers in the group). This represents a -106.8% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
19 analysts cover RCKT with a consensus rating of Buy. The consensus price target is $5.00 (range: $5.00 — $5.00), implying +40.4% upside from the current price. Grade breakdown: Strong Buy (0), Buy (13), Hold (4), Sell (2), Strong Sell (0).
The model confidence score is 53/100, based on: data completeness (0), peer quality (25), historical depth (20), earnings stability (5), and model agreement (3). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for RCKT.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.